# Cycle 1 Critique — Mechanobiology (ECM Mechanics) × Epigenomics (Enhancer Regulation)

**Session:** 2026-03-26-targeted-001
**Critic model:** opus (BLIND MODE — parametric knowledge only, no WebSearch/WebFetch)
**Cycle:** 1
**Hypotheses critiqued:** 7
**Kill rate:** 2/7 (29%)
**Mode:** BLIND — all 9 attack vectors applied using parametric knowledge only

---

## C1-H1: ECM Stiffness Nucleates Mechanosensitive Super-Enhancers via YAP-Dependent BRD4/MED1 Phase Condensate Assembly

### VERDICT: SURVIVE_REVISED
### Revised Confidence: 3/10 (down from 5)

### Attacks

**1. Novelty Kill — PARTIAL KILL (extension of known work)**
Zanconato et al., Nat Med 2018 demonstrated that oncogenic YAP/TAZ/TEAD recruits BRD4 to super-enhancers in breast cancer. This is cited in the literature context. The core mechanism of H1 — YAP → EP300 → H3K27ac → BRD4 → super-enhancer condensate — is mechanistically identical to Zanconato's pathway, with the only difference being the upstream trigger (ECM stiffness vs. oncogenic YAP amplification). The "mechano-super-enhancer" concept is therefore an **extension of known work**, not a genuinely novel connection. The novelty survives only in the specific claim that ECM stiffness gradients produce graded super-enhancer catalogs, and that the phase separation threshold provides a switch-like behavior not seen with simple YAP target activation. This is incremental novelty, not transformative novelty.

Search equivalent (parametric): "YAP TAZ BRD4 super-enhancer" → Zanconato Nat Med 2018 is a direct hit. "ECM stiffness super-enhancer" → 0 papers per computational validation. The connection exists via Zanconato; the stiffness angle is partially novel.

**2. Mechanism Kill — WOUNDED**
The mechanism chain (stiffness → YAP → EP300 → H3K27ac → BRD4 phase separation → condensate) is plausible but has quantitative uncertainties:
- EP300 kcat ~5/min is an in vitro estimate on histone peptides; in vivo rates on nucleosomal substrates are 10-100x slower due to chromatin compaction and competing modifications
- BRD4 phase separation threshold (~5-10 µM from Sabari 2018) was measured for MED1 IDR, not BRD4 specifically. The BRD4 phase separation field has been contentious — McSwiggen et al. (eLife 2019) challenged hub/condensate models at super-enhancers using single-molecule imaging, finding BRD4 clusters were smaller and more dynamic than predicted by the phase separation model
- Whether sustained YAP occupancy over hours produces enough H3K27ac to cross the phase separation threshold (vs. reaching a steady-state that is below-threshold) is quantitatively unknown
- The phase separation model of super-enhancers itself is contested in the field

**3. Logic Kill — MINOR**
The bisociation between "supertranscription factor" (Amar 2021) and "super-enhancer" is a naming coincidence, not a structural analogy. Force activating many genes simultaneously (Amar's concept) operates through a completely different mechanism than super-enhancers (clustered cis-regulatory elements). The cleverness of the naming parallel does not constitute evidence for a mechanistic link.

**4. Falsifiability Kill — PASSES**
The H3K27ac ChIP-seq + BRD4 ChIP-seq across stiffness gradient is an excellent experimental design. The JQ1 control is appropriate. ROSE algorithm super-enhancer calling is standard. The hypothesis is clearly falsifiable.

**5. Triviality Kill — MODERATE CONCERN**
Given Zanconato 2018 (YAP → BRD4 → super-enhancers) and the well-established stiffness → YAP pathway (Dupont 2011), the inference "stiffness → YAP → super-enhancers" is a logical one-hop extension that a graduate student familiar with both papers could make. The phase separation angle adds some non-triviality, but the core prediction is fairly obvious given the literature.

**6. Counter-Evidence (parametric)**
- The phase separation model of super-enhancers has been challenged. McSwiggen et al. (eLife 2019) used single-molecule imaging and found that BRD4 does not form large, stable condensates at super-enhancers in living cells — rather, it forms transient, small clusters. If BRD4 doesn't truly phase-separate at super-enhancers, the condensate nucleation model collapses.
- 1,6-hexanediol, commonly used to disrupt phase separation, also disrupts normal protein-chromatin interactions, making it an unreliable tool to test condensate function specifically. JQ1 is better but acts via BRD4 bromodomain inhibition, not condensate disruption per se.
- Chong et al. (Science 2018) showed that super-enhancer–associated condensates have properties inconsistent with simple liquid-liquid phase separation.

**7. Groundedness — 50%**
| Claim | Status |
|-------|--------|
| YAP nuclear translocation on stiff substrates (Dupont 2011) | GROUNDED ✓ |
| EP300-BRD4 interaction (STRING 0.988) | GROUNDED ✓ |
| YAP-BRD4 co-occurrence (31 PubMed papers) | GROUNDED ✓ (count unverifiable but co-occurrence real) |
| ECM stiffness + H3K27ac = 0 papers | GROUNDED ✓ (computational validation) |
| BRD4 phase separation threshold 5-10 µM in vivo | PARAMETRIC ✗ (Sabari showed MED1, not BRD4) |
| EP300 kcat ~5/min in vivo | PARAMETRIC ✗ (no source, in vitro only) |
| Sustained YAP crosses condensate nucleation threshold | PARAMETRIC ✗ |
| Mechano-super-enhancers as distinct category | PARAMETRIC ✗ |

4/8 claims grounded = 50%.

**8. Hallucination-as-Novelty Check**
The hypothesis scores lower on novelty than initially presented because Zanconato 2018 already established the YAP → BRD4 → super-enhancer axis. The "novel" aspect (ECM stiffness as trigger) is real but incremental. The phase separation framing adds apparent novelty but the underlying BRD4 condensate model at super-enhancers is contested. The novelty is NOT hallucinated — the components exist — but it is INFLATED by the Zanconato overlap.

**9. Claim-Level Fact Verification**
- "Dupont, Nature 2011" — VERIFIED: Dupont et al., "Role of YAP/TAZ as mechanotransducers," Nature 2011. Real paper, correct journal. ✓
- "Sabari, Science 2018" — VERIFIED: Sabari et al., "Coactivator condensation at super-enhancers links phase separation and gene control," Science 2018. Real paper. However, showed MED1 IDR phase separation, not BRD4 specifically. The hypothesis extrapolates to BRD4 without explicit citation for BRD4 phase separation. ⚠️
- "Hnisz, Cell 2013" — VERIFIED: Hnisz et al., "Super-enhancers in the control of cell identity and disease," Cell 2013. Real paper. ✓
- EP300 kcat ~5/min — UNVERIFIABLE: No citation provided. Likely inferred from in vitro acetyltransferase assays. ✗
- "31 PubMed papers" for YAP-BRD4 — Cannot verify exact count. Co-occurrence is plausible but number is unverifiable. ⚠️

No citation hallucinations detected, but BRD4 phase separation is attributed to Sabari 2018 which actually showed MED1. This is a significant misattribution, though not fabrication.

### Survival Note
Survives because the experimental prediction (H3K27ac/BRD4 ChIP-seq across stiffness gradient) would genuinely fill a gap (0 papers on ECM stiffness + H3K27ac). However, the novelty is substantially reduced by Zanconato 2018, the phase separation model is contested, and the hypothesis should be reframed as "testing whether the Zanconato YAP-super-enhancer mechanism operates under physiological stiffness gradients" rather than claiming a new connection.

---

## C1-H2: LINC-Transmitted Mechanical Force Detaches Enhancers from LADs, Creating Stiffness-Dependent Enhancer Derepression

### VERDICT: KILLED
### Revised Confidence: 2/10 (down from 4)

### Attacks

**1. Novelty Kill — PASSES**
No prior work directly connects LINC-transmitted force to physical LAD boundary detachment and enhancer derepression. The concept is genuinely novel.

**2. Mechanism Kill — FATAL**
The quantitative force distribution problem is irreconcilable:
- Computational validation: total force at nucleus = 120 pN (passive) to 920 pN (active+passive)
- Number of lamin-chromatin contacts: the hypothesis estimates ~100,000, which is conservative; the actual number may be higher (100,000-500,000 based on DamID contact frequency)
- Force per contact: 120/100,000 = 0.0012 pN (best case: 920/100,000 = 0.0092 pN)
- The hypothesis states "30 pN / 100k = 0.3 pN" which uses a lower total force but the math yields the same conclusion: far below the multi-pN forces needed for physical detachment
- Even with extreme stress concentration at fLAD boundaries (factor of 10-50x, which exceeds typical engineering stress concentration factors), the per-contact force reaches at most 0.05-0.5 pN — still insufficient

Furthermore, LAD tethering is primarily **biochemical**, not mechanical:
- HP1α/β/γ binding to H3K9me2/3 creates multivalent interactions at LADs
- LBR (lamin B receptor) binds both lamin B and H3K9me2/3
- These are protein-protein and protein-histone interactions, not mechanical contacts susceptible to piconewton forces
- Biochemical dissociation constants (Kd) for HP1-H3K9me interactions are in the µM range, corresponding to binding energies of ~15 kBT (~60 pN·nm), requiring ~10 pN over nm distances to mechanically disrupt — far above available per-contact forces

**3. Logic Kill — MODERATE**
The lamin A/C "force conductor" argument is internally contradictory. The hypothesis claims lamin A/C stiffens the lamina into a "rigid linkage" that transmits more force to fLAD boundaries. But increased lamin A/C also:
- Increases LAD tethering strength (lamin A/C directly anchors LADs via emerin, BAF)
- Creates a stiffer nuclear shell that distributes force more evenly (reducing stress concentration)
- Both effects OPPOSE the proposed detachment mechanism

The hypothesis selectively interprets lamin A/C stiffening as beneficial for its mechanism while ignoring the equally plausible interpretation that it strengthens LAD anchoring. This is a cherry-picking logic error.

**4. Falsifiability Kill — PASSES**
DamID-seq + H3K27ac ChIP-seq is a well-designed experiment. Falsifiable.

**5. Triviality Kill — PASSES**
The LAD detachment by force concept is non-obvious and genuinely creative.

**6. Counter-Evidence (parametric)**
- **Sun 2020** (cited in the literature context) showed that nuclear periphery genes RESIST force-induced activation due to H3K9me3 enrichment. This is direct counter-evidence: the very paper the hypothesis builds on found that LAD-region genes are PROTECTED from force, not derepressed by it.
- Cells migrating through confined spaces (3 µm pores) experience nuclear deformations far exceeding those from ECM stiffness (>30% nuclear volume change). Multiple studies (Denais et al., Science 2016; Raab et al., Science 2016) showed nuclear envelope rupture and DNA damage but NOT systematic LAD reorganization. If massive physical nuclear deformation doesn't detach LADs, subtle stiffness-mediated forces won't either.
- DamID studies during immune cell migration through tight spaces show remarkably stable LAD organization despite extreme nuclear deformation.

**7. Groundedness — 45%**
| Claim | Status |
|-------|--------|
| LADs: 35-40% genome (Guelen 2008) | GROUNDED ✓ |
| LINC complex (STRING 0.999) | GROUNDED ✓ |
| fLAD/cLAD distinction (Meuleman 2013) | GROUNDED ✓ |
| LAP2β force-chromatin (Sun 2023) | GROUNDED ✓ |
| Lamin A/C upregulation (Xu 2023, Mandal 2025) | GROUNDED ✓ |
| Physical LAD detachment by force | PARAMETRIC ✗ |
| Lamin A/C as rigid force conductor | PARAMETRIC ✗ |
| Directional/anisotropic derepression | PARAMETRIC ✗ |
| Tethering force per contact | PARAMETRIC ✗ |
| 30 pN distributed yields sufficient force | PARAMETRIC ✗ (quantitatively refuted) |
| fLAD boundary stress concentration | PARAMETRIC ✗ |

5/11 = 45% grounded.

**8. Hallucination-as-Novelty Check**
The novelty is genuine — no one has proposed physical LAD detachment by LINC force. However, the novelty may exist precisely BECAUSE the mechanism is quantitatively impossible. This is a classic case where apparent novelty signals incorrectness: no one proposed it because the numbers don't work.

**9. Claim-Level Fact Verification**
- "Guelen et al., Nature 2008" — VERIFIED ✓
- "Meuleman et al., Genome Research 2013" — VERIFIED ✓ (fLAD/cLAD paper)
- "Sun 2023, Acta Biomaterialia, LAP2β" — VERIFIED ✓ (from literature context)
- "Wang & Bhatt, NatRevMolCellBio" — Cannot verify specific authors/journal for LINC force measurements. This citation is vague. ⚠️
- Lamin B1 tethering force "estimated at low piconewton range" — UNVERIFIABLE, no citation. ✗
- 30 pN / 100k contacts = 0.3 pN — Math correct, but the conclusion (insufficient) undermines the hypothesis.

No clear citation hallucinations, but the "Wang & Bhatt" reference is suspiciously vague.

### Kill Rationale
Three independent fatal flaws converge:
1. **Quantitative insufficiency**: Force per lamin-chromatin contact is 100-1000x below detachment threshold
2. **Biochemical tethering**: LAD anchoring is primarily biochemical (HP1-H3K9me2/3, LBR-lamin), not mechanical, and cannot be overcome by piconewton forces
3. **Direct counter-evidence**: Sun 2020 showed LAD-region genes resist force-induced activation; confined migration studies show LAD stability under extreme deformation

---

## C1-H3: ECM Stiffness Coordinates a Dual-Enzyme Bivalent-to-Active Enhancer Switch via Concurrent KDM6B Activation and YAP-EP300 Recruitment

### VERDICT: SURVIVE_REVISED
### Revised Confidence: 4/10 (down from 6)

### Attacks

**1. Novelty Kill — PASSES**
No prior work connects the simultaneous mechanosensitivity of KDM6B (demethylase) and YAP-EP300 (acetyltransferase) as a coordinated enhancer switch. The literature context confirms KDM6B mechanosensitivity (Yu 2025) and YAP-EP300 recruitment independently, but their coordination at the same enhancer loci has never been proposed or tested. Genuinely novel.

**2. Mechanism Kill — SIGNIFICANT ISSUES**

**Issue A: KDM6B vs. UTX (KDM6A) at enhancers.** This is the single most important mechanistic concern. In the canonical enhancer regulation literature:
- UTX (KDM6A), not KDM6B (JMJD3), is the H3K27me3 demethylase associated with ENHANCER regulation
- UTX is a core component of the MLL3/4-COMPASS complex, which is the primary enhancer-associated H3K27me3 demethylase complex
- KDM6B (JMJD3) is more commonly associated with PROMOTER regulation, inflammatory gene induction (activated by NF-κB), and stimulus-response transcription
- Yu 2025 showed KDM6B upregulation by ECM stiffness, but their targets were EMT-associated genes (Snail, Twist PROMOTERS), not enhancers
- The hypothesis assumes KDM6B acts at distal enhancers, but evidence for KDM6B at distal enhancers is limited compared to UTX

If the mechanosensitive demethylase at enhancers is actually UTX rather than KDM6B, the hypothesis needs fundamental revision. GSK-J4 inhibits both KDM6A and KDM6B, so the proposed experiment cannot distinguish them.

**Issue B: Temporal mismatch.** YAP nuclear translocation occurs in 15-60 minutes (Dupont 2011). KDM6B upregulation requires transcription and translation — minimum 2-6 hours for new protein. Therefore:
- EP300 arrives at enhancers HOURS before KDM6B levels increase
- The "coordinated, simultaneous" operation is actually SEQUENTIAL
- EP300 may acetylate non-bivalent enhancers first (those without H3K27me3), then KDM6B clears H3K27me3 at bivalent loci hours later, then EP300 acetylates those too
- This changes the prediction from "simultaneous dual-enzyme switch" to "two-wave sequential enhancer activation"

**Issue C: PRC2 kinetic competition.** At bivalent/poised enhancers, PRC2 (EZH2) is constitutively active re-methylating H3K27. KDM6B must out-compete PRC2 demethylation. At physiological KDM6B concentrations, this competition may be unfavorable at many loci, limiting the switch to high-KDM6B-concentration conditions.

**3. Logic Kill — MINOR**
The claim that "ECM stiffness uniquely coordinates BOTH arms" is overclaimed. Other stimuli also activate both pathways:
- Inflammatory cytokines (TNFα) upregulate KDM6B (via NF-κB) and can activate EP300 (via various signaling cascades)
- Differentiation signals (BMP, retinoic acid) activate KDM6B and recruit coactivators including EP300
- The "unique to ECM stiffness" claim requires evidence that no other stimulus does this, which is unprovable

**4. Falsifiability Kill — PASSES**
Excellent experimental design. CUT&Tag for H3K27me3 + H3K27ac across stiffness gradients with pharmacological perturbation. The combinatorial GSK-J4 + A-485 experiment is particularly well-designed.

**5. Triviality Kill — PASSES**
The coordination of KDM6B and EP300 at the same enhancers is not obvious. Neither field would trivially predict this.

**6. Counter-Evidence (parametric)**
- KDM6B targets in Yu 2025 (Snail, Twist) are EMT genes, not developmental enhancers. There may be minimal overlap between KDM6B targets and YAP-TEAD-EP300 targets (CTGF, CYR61). If the two enzymes operate at DIFFERENT loci, the "coordinated switch at the same enhancers" claim fails.
- GSK-J4 at 10 µM has significant off-target effects: it inhibits both KDM6A and KDM6B (and partially inhibits other JmjC demethylases at high concentrations). The proposed experiment cannot distinguish KDM6B from KDM6A contributions. Genetic approaches (siKDM6B vs siKDM6A) are essential but not included in the primary protocol.

**7. Groundedness — 55%**
| Claim | Status |
|-------|--------|
| KDM6B demethylates H3K27me3 | GROUNDED ✓ (canonical) |
| ECM stiffness upregulates KDM6B (Yu 2025) | GROUNDED ✓ |
| EP300 writes H3K27ac | GROUNDED ✓ (canonical) |
| H3K27me3/H3K27ac mutual exclusivity | GROUNDED ✓ (biochemical fact) |
| YAP-TEAD recruits EP300 (STRING 0.692) | PARTIALLY GROUNDED ✓ |
| Poised enhancers (Rada-Iglesias 2011) | GROUNDED ✓ |
| KDM6B and EP300 at SAME loci | PARAMETRIC ✗ |
| KDM6B activation is YAP-independent | PARAMETRIC ✗ |
| Unique to ECM stiffness | PARAMETRIC ✗ |
| Combinatorial > individual inhibition | PARAMETRIC ✗ |

6/10 = 60% (rounding down to 55% due to partial grounding of YAP-EP300).

**8. Hallucination-as-Novelty Check**
Both enzyme activities (KDM6B mechanosensitivity, EP300 recruitment via YAP) are independently verified. The coordination claim is parametric but not hallucinated — it's a reasonable inference from the independent observations. Low hallucination risk. However, the KDM6B-at-enhancers assumption may be incorrect (UTX is the canonical enhancer demethylase), which would undermine the mechanism without being a "hallucination."

**9. Claim-Level Fact Verification**
- "KDM6B (JMJD3) demethylates H3K27me3" — VERIFIED ✓ (canonical enzymology)
- "Yu et al., MCB 2025, KDM6B upregulation by stiffness" — GROUNDED per literature context (near cutoff paper) ✓
- "Rada-Iglesias et al., Nature 2011" — VERIFIED ✓ (poised enhancers paper, correct journal/year)
- "Bernstein Cell 2006" — VERIFIED ✓ (bivalent chromatin paper)
- "Whitworth 2024, EP300 for mechanoresponsive transcription" — Cannot fully verify from parametric knowledge. Journal not specified. ⚠️
- "H3K27me3 and H3K27ac mutually exclusive on same K27" — VERIFIED ✓ (biochemical fact: same residue, can't be both modified)

No citation hallucinations detected. The Whitworth 2024 reference is uncertain but not suspicious.

### Survival Note
Survives as the strongest hypothesis in the set. The coordinated dual-enzyme mechanism is genuinely novel and fills a clear literature gap (Anomaly #3). However, three significant issues must be addressed: (1) UTX vs KDM6B at enhancers — the hypothesis may need to be reformulated around UTX; (2) temporal mismatch requiring reframing as sequential, not simultaneous; (3) target overlap between KDM6B and YAP-TEAD-EP300 is assumed, not demonstrated. Despite these, the core idea (ECM stiffness activates both the eraser and writer for the H3K27me3→H3K27ac switch) is mechanistically elegant and testable.

---

## C1-H4: Stiffness-Induced Enhancer H3K27ac Creates Self-Sustaining Transcriptional Condensates That Persist as Mechanical Memory

### VERDICT: SURVIVE_REVISED
### Revised Confidence: 3/10 (down from 5)

### Attacks

**1. Novelty Kill — PASSES**
Mechanical memory is established (Yang 2014) but no one has proposed the specific H3K27ac → BRD4 → eRNA → condensate → EP300 → H3K27ac feedback loop as the molecular mechanism. This is genuinely novel at the mechanism level.

**2. Mechanism Kill — SEVERE QUANTITATIVE ISSUES**

**Issue A: H3K27ac turnover.** Metabolic labeling studies (various groups using isotope tracing) have measured H3K27ac half-life at active enhancers at approximately 2-6 hours. HDACs (primarily HDAC1, HDAC2, HDAC3) constitutively remove H3K27ac. For the feedback loop to self-sustain without YAP-EP300 recruitment, the condensate-trapped EP300 must write H3K27ac faster than HDACs erase it. Critically:
- Once YAP exits the nucleus (1-4 hours on soft substrate), EP300 is no longer actively recruited to the locus
- Whatever EP300 remains in the condensate is a finite, non-replenished pool
- BRD4 FRAP shows recovery in seconds (Sabari 2018), meaning BRD4 is NOT stably trapped — it exchanges rapidly
- If BRD4 exchanges in seconds, the condensate is highly dynamic, and EP300 would similarly be dynamic
- The condensate therefore CONCENTRATES but does not TRAP enzymes
- Once the YAP signal stops, the steady-state EP300 concentration at the locus drops, shifting the writing/erasing balance toward net H3K27ac loss

The feedback loop may extend H3K27ac persistence by 2-3x (from ~4 hr to ~8-12 hr) but is unlikely to sustain it for 24-72 hours as claimed.

**Issue B: eRNA instability.** eRNAs are among the most unstable RNA species in the cell:
- Half-lives measured at 5-30 minutes (much shorter than mRNAs)
- Rapidly degraded by the RNA exosome
- eRNA levels track closely with enhancer activity — they do not persist after enhancer inactivation
- If the condensate depends on eRNAs for stabilization, it will dissolve within minutes of transcription cessation
- Transcription cessation would follow H3K27ac loss → reduced BRD4 → reduced P-TEFb → reduced Pol II → reduced eRNA → condensate collapse

This creates a NEGATIVE feedback loop (rapid collapse) rather than the positive feedback loop claimed.

**Issue C: Timescale mismatch with Yang 2014.** Yang et al. (2014, likely Nature Materials) showed mechanical memory requires >10 days of stiffness exposure. The hypothesis claims enhancer-level memory could establish in 48-72 hours. If enhancer feedback loops establish faster than the observed whole-cell memory, this suggests enhancers are NOT the primary memory mechanism — DNA methylation, chromatin compaction, or other more stable modifications may be responsible.

**3. Logic Kill — MODERATE**
The hypothesis assumes a positive feedback loop can maintain itself, but this is an extraordinary claim requiring quantitative justification. Most biological positive feedback loops either (a) require continuous external input to sustain, or (b) switch to a new stable state (bistability) mediated by DNA-level changes. The proposed H3K27ac-BRD4-eRNA loop has no obvious bistability mechanism — it's a single continuous feedback without a mechanism to "lock" the on-state.

**4. Falsifiability Kill — PASSES**
Excellent time-course design. The JQ1-at-transfer experiment is a clever test of the feedback mechanism.

**5. Triviality Kill — PASSES**
The specific molecular mechanism for mechanical memory is not obvious.

**6. Counter-Evidence (parametric)**
- H3K27ac turnover (~2-6 hr half-life) is the primary counter-evidence. Multiple metabolic labeling studies establish this timescale.
- HDAC inhibitor studies show that H3K27ac levels rapidly increase genome-wide, confirming constitutive HDAC activity at all H3K27ac-marked loci. Once EP300 recruitment drops, HDACs will erase H3K27ac on a timescale of hours.
- BRD4 condensate inhibition by JQ1 causes transcriptional changes within 1-2 hours, not the 24-72 hours that would be expected if condensates were self-sustaining for that duration.

**7. Groundedness — 50%**
| Claim | Status |
|-------|--------|
| Mechanical memory (Yang 2014) | GROUNDED ✓ (concept real; journal may be Nat Mat not Science) |
| Mechanical memory as epigenetic (Hsia 2023) | GROUNDED ✓ |
| H3K27ac → BRD4 → P-TEFb | GROUNDED ✓ (canonical) |
| eRNAs from active enhancers | GROUNDED ✓ (canonical) |
| BRD4 FRAP ~seconds (Sabari 2018) | GROUNDED ✓ |
| eRNAs stabilize condensates | PARAMETRIC ✗ (Henninger 2021 showed RNA generally) |
| EP300 writing rate exceeds HDAC erasing rate | PARAMETRIC ✗ |
| Feedback establishes in 48-72h | PARAMETRIC ✗ |
| Condensate lifetime hours-to-days | PARAMETRIC ✗ |
| Memory follows condensate kinetics | PARAMETRIC ✗ |

5/10 = 50%.

**8. Hallucination-as-Novelty Check**
The individual components (H3K27ac, BRD4, eRNAs, condensates) are all real. The feedback loop concept is parametric but not hallucinated. However, the claim that this loop is self-sustaining may be "novel" precisely because it is quantitatively impossible — the eRNA instability and H3K27ac turnover rates preclude self-sustenance. The novelty may partially reflect an incorrect model.

**9. Claim-Level Fact Verification**
- "Yang et al., Science 2014" — PARTIALLY VERIFIED: Yang et al. showed mechanical memory in MSCs. The journal may be Nature Materials 2014, not Science. The concept and lab are real. ⚠️ (potential journal misattribution)
- "Hsia et al., J Mol Biol, 2023" — Cannot fully verify journal from parametric knowledge but the concept is consistent with the field. ⚠️
- "Henninger et al., Cell 2021" — VERIFIED ✓ (Henninger, Oksuz et al., RNA-mediated transcriptional condensation, Cell 2021. However, showed RNA broadly, not specifically eRNAs at enhancers)
- "Sigova et al., Science 2015" — VERIFIED ✓ (Sigova showed eRNAs recruit coactivators)
- H3K27ac → BRD4 → P-TEFb — VERIFIED ✓ (canonical)

The Yang 2014 journal attribution is uncertain but the underlying biology is real. Not a hallucination.

### Survival Note
Survives because the concept of enhancer-level mechanical memory is worth testing, and the experimental design is excellent. However, the self-sustaining feedback loop is almost certainly too short-lived to explain the timescales of mechanical memory observed by Yang et al. The hypothesis should be revised to: (1) predict much shorter memory timescale (6-12 hours, not 24-72), (2) acknowledge that longer-term memory likely requires additional mechanisms (DNA methylation, chromatin compaction), and (3) position the enhancer feedback loop as a SHORT-TERM bridge that buys time for longer-term memory mechanisms to engage.

---

## C1-H5: ECM Stiffness Rewires Enhancer-Promoter 3D Chromatin Loops via YAP-TEAD-Dependent NIPBL Recruitment and Cohesin Redistribution

### VERDICT: SURVIVE_REVISED
### Revised Confidence: 3/10 (down from 4)

### Attacks

**1. Novelty Kill — MODERATE**
No Hi-C or HiChIP data exists under ECM stiffness gradients (per literature gap #3). The experimental data would be novel. However, the MECHANISM is a trivial extension of known enhancer biology: active enhancers recruit cohesin via NIPBL (Kagey 2010), BRD4 interacts with NIPBL (Olley 2018), and stiffness activates enhancers (via YAP). Therefore: stiffness → active enhancers → cohesin → loops. This is a straightforward inference, not a creative connection.

**2. Mechanism Kill — SIGNIFICANT ISSUES**

**Issue A: The 6-step cascade.** The chain (stiffness → YAP → EP300 → H3K27ac → BRD4 → NIPBL → cohesin → loops) contains 7 sequential steps. Each step transmits only a fraction of the upstream signal. Quantitative concern: if each step has 50% efficiency (generous), the final signal is 0.5^7 = 0.8% of the original. New loop formation may require substantial cohesin redistribution that this attenuated signal cannot achieve.

**Issue B: CTCF dominance in loop formation.** The prevailing model of chromatin loop formation emphasizes CTCF boundary elements as the primary determinants of loop anchors. While enhancer-driven cohesin loading contributes to some loops, the majority of detectable loops by Hi-C are CTCF-anchored. Enhancer-promoter contacts often occur within existing TADs without requiring new cohesin-mediated loops — they may depend on proximity and condensate-mediated interactions instead.

**Issue C: BRD4-NIPBL generalizability.** The Olley 2018 paper studied BRD4-NIPBL in the context of Cornelia de Lange syndrome (CdLS), where NIPBL haploinsufficiency creates a specific pathological context. Whether BRD4-NIPBL interaction is quantitatively significant in normal enhancer biology (where NIPBL is present at normal levels) is unclear. The interaction may be a minor contribution masked by other NIPBL recruitment mechanisms.

**3. Logic Kill — TRIVIALITY CONCERN**
The hypothesis essentially states: "If ECM stiffness changes enhancer activity (via YAP), and active enhancers recruit cohesin loaders, then ECM stiffness changes cohesin-mediated loops." This is logically valid but trivially follows from the premises. The intellectual contribution is the experimental prediction (HiChIP under stiffness), not the mechanism, which is an obvious deduction.

**4. Falsifiability Kill — PASSES**
H3K27ac HiChIP is well-designed and technically feasible. The perturbation panel (siNIPBL, JQ1, verteporfin) is comprehensive.

**5. Triviality Kill — SIGNIFICANT**
A graduate student who knows (1) stiffness → YAP → active enhancers, (2) active enhancers recruit cohesin via NIPBL, and (3) cohesin forms loops, could trivially predict "stiffness → different loops." The hypothesis adds the BRD4-NIPBL step, which adds some specificity, but the overall conclusion is predictable.

**6. Counter-Evidence (parametric)**
- **Auxin-induced cohesin degradation** (Rao et al., Cell 2017) showed that complete cohesin removal abolishes loops but TADs reform rapidly upon cohesin restoration, suggesting loop positions are genetically determined by CTCF boundaries, not dynamically by enhancer-driven NIPBL loading.
- TAD structures are remarkably STABLE under strong perturbations (transcription inhibition, cohesin degradation + restoration, cell cycle manipulation). If global perturbations barely change TAD architecture, subtle enhancer-driven cohesin redistribution by stiffness is unlikely to produce detectable new loops.
- Phase separation models of enhancer-promoter interaction (Hnisz 2017) suggest that enhancer-promoter contacts can occur via condensate-mediated proximity within existing TADs without requiring new cohesin-mediated loops.

**7. Groundedness — 45%**
| Claim | Status |
|-------|--------|
| NIPBL at enhancers (Kagey 2010) | GROUNDED ✓ |
| Cohesin loop extrusion | GROUNDED ✓ (canonical) |
| BRD4-NIPBL (Olley 2018) | PARTIALLY GROUNDED ⚠️ |
| H3K27ac read by BRD4 | GROUNDED ✓ (canonical) |
| YAP-TEAD-EP300 (STRING 0.692) | PARTIALLY GROUNDED ⚠️ |
| Stiffness → cohesin redistribution via full chain | PARAMETRIC ✗ |
| New enhancer-promoter loops on stiff substrates | PARAMETRIC ✗ |
| Loops functionally distinct from CTCF loops | PARAMETRIC ✗ |
| BRD4-NIPBL is general (not CdLS-specific) | PARAMETRIC ✗ |

4.5/9 ≈ 50% → rounding to 45% due to partial grounding.

**8. Hallucination-as-Novelty Check**
The BRD4-NIPBL interaction (Olley 2018) is a real published finding. The hypothesis does not fabricate components. However, the "novelty" of predicting stiffness-dependent loops is low because it trivially follows from known premises. The hypothesis is not hallucinated but may be trivial.

**9. Claim-Level Fact Verification**
- "Kagey et al., Nature 2010" — VERIFIED ✓ (Mediator and cohesin occupy enhancers, real paper)
- "Olley et al., Nature Genetics 2018" — LIKELY VERIFIED ✓ (CdLS/BRD4/NIPBL paper, confident about authors and approximate year, may be 2018)
- "Fudenberg et al., Cell Reports 2016" — VERIFIED ✓ (loop extrusion model)
- "Rao et al., Cell 2017" — VERIFIED ✓ (cohesin degradation experiments)
- "Mumbach et al., Nature Methods 2016" — VERIFIED ✓ (HiChIP method paper)

No citation hallucinations detected.

### Survival Note
Survives because the experimental data (HiChIP under stiffness) would genuinely be novel and informative regardless of which loops are found. However, the mechanism is largely a trivial extension of known enhancer-cohesin biology, the 6-step cascade may be quantitatively insufficient, and CTCF-determined loop architecture may be too robust for enhancer-driven redistribution to produce detectable changes. The hypothesis should be reframed as an "experimental prediction" rather than a "mechanistic discovery."

---

## C1-H6: Tissue-Specific ECM Stiffness Selects Tissue-Specific Enhancer Programs Through Differential YAP Nuclear Residence Time and EP300 Occupancy Kinetics

### VERDICT: SURVIVE_REVISED
### Revised Confidence: 3/10 (down from 5)

### Attacks

**1. Novelty Kill — MODERATE**
The concept of stiffness directing differentiation is well-established (Engler 2006). The kinetic selection model (YAP dwell time → enhancer hierarchy) adds a mechanistic layer that hasn't been explicitly proposed. However, the idea that "graded signal → graded transcriptional output" is a general principle in signaling biology, and applying it to YAP is a natural extension.

**2. Mechanism Kill — FATAL CONCEPTUAL FLAW**

**Issue A: Lineage-specific TFs, not YAP, determine tissue-specific enhancers.** This is the critical problem. Tissue-specific enhancer programs are defined by tissue-specific transcription factors:
- Muscle enhancers: MYOD, MYF5, MEF2C
- Bone enhancers: RUNX2, OSX/SP7
- Adipocyte enhancers: PPARγ, C/EBPα
- Neuronal enhancers: NEUROD, BRN2, SOX2

YAP-TEAD activates a SPECIFIC set of enhancers (those with TEAD binding sites: CTGF, CYR61, ANKRD1, AMOTL2, etc.). These are NOT tissue-specific — they are shared across cell types as general proliferation/survival enhancers. YAP CANNOT activate a MYOD enhancer (which requires MYOD protein) regardless of how much nuclear YAP there is or how long it resides in the nucleus.

The hypothesis conflates two different phenomena:
1. YAP quantitatively modulating its OWN target enhancers at different stiffnesses (probably true, but these are the same enhancers at all stiffnesses — just active vs. inactive)
2. YAP selecting DIFFERENT, tissue-specific enhancer programs at different stiffnesses (almost certainly false — YAP targets TEAD-motif enhancers in all tissues)

**Issue B: The "morphogen" analogy is structurally flawed.** Morphogens (Shh, BMP, Wnt) activate DIFFERENT downstream pathways at different concentrations through distinct receptors and effectors (e.g., Gli1 vs Gli2/3, different Smads). This produces qualitatively different transcriptional programs. YAP-TEAD, by contrast, always activates the SAME downstream pathway (TEAD-bound genes). More YAP = more of the same genes activated, not DIFFERENT genes. The analogy fails at the structural level.

**Issue C: Stiffness in differentiation is permissive, not instructive.** Engler 2006 showed stiffness directs MSC differentiation, but subsequent work has shown that stiffness is PERMISSIVE rather than INSTRUCTIVE — it enables differentiation programs initiated by lineage-specific signals, rather than selecting them. On osteogenic-stiff substrates in the absence of osteogenic supplements, MSCs do NOT robustly differentiate into osteoblasts. YAP activity supports but does not select the lineage program.

**3. Logic Kill — SIGNIFICANT**
The prediction that "enhancer profiles at each stiffness should resemble native tissue profiles" (prediction d) is almost certainly false. MSCs on 12 kPa will NOT have a muscle-like enhancer profile because they lack MYOD. They will have an MSC enhancer profile with graded YAP target activation. Confusing YAP-responsive enhancers with tissue-specific enhancers is a category error.

**4. Falsifiability Kill — PASSES (but prediction likely false)**
The stiffness gradient H3K27ac ChIP-seq experiment is technically feasible and well-designed. The comparison to ENCODE tissue profiles is an excellent idea — but will likely show that stiffness-dependent enhancers do NOT match tissue-specific profiles, falsifying the hypothesis.

**5. Triviality Kill — PARTIAL**
Graded YAP → graded enhancer activation at TEAD sites is a relatively obvious prediction. The tissue-specific interpretation is where the hypothesis over-reaches.

**6. Counter-Evidence (parametric)**
- MSCs on osteogenic stiffness (30+ kPa) WITHOUT osteogenic supplements (dexamethasone, BMP-2) show only modest osteogenic gene upregulation. Full differentiation requires both stiffness AND lineage-specific signals. This contradicts the "stiffness alone selects tissue-specific enhancers" claim.
- YAP/TAZ are actually ANTAGONISTIC to some tissue-specific differentiation programs. For example, YAP must be DOWNREGULATED for proper adipogenesis — active YAP on any stiffness substrate INHIBITS adipocyte-specific enhancers. This directly contradicts the prediction that soft substrates (adipose-like stiffness) would activate adipose-like enhancers via a "low YAP" state.
- Chondrocyte differentiation (cartilage stiffness ~20-30 kPa) requires SOX9, not YAP. YAP can actually inhibit chondrogenesis.

**7. Groundedness — 45%**
| Claim | Status |
|-------|--------|
| Graded YAP (Elosegui-Artola 2017) | GROUNDED ✓ |
| Tissue stiffness values (Engler 2006) | GROUNDED ✓ |
| YAP-TEAD recruits EP300 (STRING 0.692) | PARTIALLY GROUNDED ⚠️ |
| Stiffness → MSC differentiation (Engler 2006) | GROUNDED ✓ |
| EP300 residence time determines H3K27ac | PARAMETRIC ✗ |
| TEAD motif affinity = activation threshold | PARAMETRIC ✗ |
| Hierarchical (not distinct) enhancer activation | PARAMETRIC ✗ |
| Stiffness profiles match tissue profiles | PARAMETRIC ✗ (likely false) |
| Stiffness as morphogen | PARAMETRIC ✗ (analogy breaks) |

3.5/9 ≈ 40% → adjusted to 45%.

**8. Hallucination-as-Novelty Check**
The "stiffness as morphogen" framework is novel precisely because it's wrong — it applies a morphogen model (qualitatively different outputs at different concentrations) to YAP signaling (quantitatively different output of the same program). This is a subtle but important error. The novelty is an artifact of the incorrect analogy.

**9. Claim-Level Fact Verification**
- "Elosegui-Artola et al., Cell 2017" — VERIFIED ✓ (real paper on graded YAP mechanosensing)
- "Engler et al., Cell 2006" — VERIFIED ✓ (classic MSC stiffness-directed differentiation)
- "Dupont et al., Nature 2011" — VERIFIED ✓
- "Levental et al., Soft Matter 2007" — LIKELY VERIFIED ✓ (tissue stiffness measurements; journal uncertain)

No citation hallucinations.

### Survival Note
Survives narrowly because the experimental data (H3K27ac across stiffness gradient) would be informative regardless, and the hierarchical activation prediction at TEAD sites (predictions a-c) is testable and likely partially correct. However, the central claim — that stiffness selects tissue-specific enhancer programs — has a fundamental conceptual flaw: YAP-TEAD targets are not tissue-specific. The hypothesis should be reframed from "tissue-specific enhancer selection" to "stiffness-graded activation of YAP-TEAD target enhancers," which is a much more modest (and probably correct) claim. Prediction (d) — matching tissue profiles — should be explicitly flagged as unlikely to hold.

---

## C1-H7: Direct LINC-Transmitted Mechanical Force Functions as a Physical Pioneer Factor, Unwinding Nucleosomes at Mechanosensitive Enhancers Independent of ATP-Dependent Remodelers

### VERDICT: KILLED
### Revised Confidence: 1/10 (down from 4)

### Attacks

**1. Novelty Kill — PASSES**
The "physical pioneer factor" concept — force opening chromatin de novo at enhancers before any TF binds — is genuinely novel and creative. No prior work frames mechanical force this way.

**2. Mechanism Kill — FATAL QUANTITATIVE INSUFFICIENCY**
This is the strongest kill in the entire set.

**Force distribution calculation:**
- Total LINC force: 10-100 pN (hypothesis claim) or 120-920 pN (computational validation)
- Human genome: ~3.2 billion bp → ~30 million nucleosomes (one per ~147 bp + ~50 bp linker)
- Even using only the ~6 million nucleosomes in euchromatin: 920 pN / 6,000,000 = 0.00015 pN per nucleosome
- This is **13,000x below the 2 pN outer-wrap unwrapping threshold**
- The hypothesis uses 30 pN / 100k lamin contacts = 0.3 pN, but this conflates lamin-chromatin contacts (nuclear envelope) with nucleosomes throughout the nuclear interior. Force cannot teleport from the lamina to interior nucleosomes.

**Stress concentration argument fails:**
- Engineering stress concentration factors at material interfaces are typically 2-5x, occasionally 10x
- Even 100x stress concentration (physically unreasonable for a polymer): 0.00015 × 100 = 0.015 pN — still 130x below threshold
- Even 1000x: 0.15 pN — still 13x below threshold
- The stress concentration needed is >10,000x, which exceeds any known physical mechanism in polymer systems

**Viscoelastic dissipation:**
- Chromatin is a viscoelastic material with relaxation times of 0.1-10 seconds
- At 0.5 Hz (2-second cycles), significant stress relaxation occurs during each cycle
- The material never reaches a steady-state force distribution — forces are continuously dissipated
- Viscous dissipation further reduces the already-insufficient per-nucleosome force

**Force geometry:**
- Nucleosome unwrapping requires force applied along the DNA entry/exit points (axial force)
- LINC-transmitted force is radial (from nuclear envelope toward interior), creating compressive or shear forces on most nucleosomes
- Only nucleosomes aligned with the force axis would experience unwrapping-appropriate forces
- This further reduces the fraction of nucleosomes that could theoretically be unwrapped

**3. Logic Kill — SEVERE**
**Category error:** Chromatin is not a continuous elastic solid. The stress concentration model (analogized from cracks at material interfaces in engineering) applies to materials with well-defined interfaces, elastic behavior, and static loading. Chromatin is:
- A dynamic polymer in solution
- Continuously remodeled by motor proteins (SWI/SNF, ISWI, CHD)
- Subject to thermal fluctuations (~4 pN·nm per degree of freedom at 37°C)
- Self-organizing on timescales faster than external force application

Applying materials science stress concentration models to chromatin is a fundamental category error.

**4. Falsifiability Kill — PASSES (with caveats)**
The flavopiridol + stretch ATAC-seq experiment is clever but has confounds: flavopiridol inhibits CDK9 (P-TEFb component) which also affects cell cycle, DNA damage signaling, and other CDK-dependent processes. Changes in ATAC-seq signal could reflect CDK-dependent chromatin remodeling changes, not force-independent enhancer opening.

**5. Triviality Kill — PASSES**
The concept is creative and non-obvious.

**6. Counter-Evidence (parametric)**

**Confined migration counter-evidence (strongest):**
- Cells migrating through 3 µm pores (Denais et al., Science 2016; Raab et al., Science 2016) experience nuclear deformation exceeding 50% diameter reduction
- Nuclear forces during confined migration vastly exceed those from ECM stiffness-mediated LINC transmission
- These studies show nuclear envelope rupture and DNA damage but NOT systematic chromatin opening at enhancers
- If forces capable of rupturing the nuclear envelope cannot unwrap nucleosomes at enhancers, the much smaller LINC-transmitted forces from ECM stiffness certainly cannot

**Nuclear compression studies:**
- AFM compression of nuclei at forces of 1-10 nN (1000x above LINC forces) produces chromatin compaction, not decompaction
- This is the opposite of what the "physical pioneer" model predicts

**Thermal noise context:**
- At 37°C, thermal energy kBT ≈ 4.1 pN·nm
- Individual nucleosomes experience thermal fluctuations of ~0.5-1 pN on sub-second timescales
- The proposed per-nucleosome forces from LINC (0.00015 pN) are 3000-6000x BELOW thermal noise
- The force signal cannot be detected above thermal background

**7. Groundedness — 35%**
| Claim | Status |
|-------|--------|
| Nucleosome unwrapping ~2-3 pN | GROUNDED ✓ |
| LINC force ~10-100 pN | GROUNDED ✓ |
| LAP2β force-chromatin (Sun 2023) | GROUNDED ✓ |
| Frequency dependence (Sun 2020) | GROUNDED ✓ |
| "Physical pioneer factor" concept | PARAMETRIC ✗ |
| Stress concentration at domain boundaries | PARAMETRIC ✗ (physically implausible) |
| Chromatin Young's modulus (Shimamoto 2017) | PARAMETRIC ✗ (mitosis vs interphase) |
| 30 pN yields sufficient per-locus force | PARAMETRIC ✗ (quantitatively refuted) |
| Force opens chromatin BEFORE TF binding | PARAMETRIC ✗ |
| Selectivity via material interface analogy | PARAMETRIC ✗ (category error) |

4/10 = 40% → adjusted to 35% due to quantitative refutation of key parametric claims.

**8. Hallucination-as-Novelty Check**
This is the clearest case of "novel because wrong." The hypothesis is novel because no one else has proposed that LINC forces physically pioneer enhancers — and no one has proposed it because the numbers are ~10,000x insufficient. The creativity in framing (materials science stress concentration at chromatin boundaries) is genuine, but the novelty is an artifact of incorrectness, not of unexplored territory.

**9. Claim-Level Fact Verification**
- "Brower-Toland et al., J Mol Biol 2002" — LIKELY VERIFIED ✓ (optical tweezers nucleosome unwrapping; approximate year confident)
- "Li et al., Nat Struct Mol Biol 2005" — LESS CERTAIN ⚠️ (there are nucleosome unwrapping papers from that era but exact attribution uncertain)
- "Shimamoto et al., Cell 2017" — PARTIALLY VERIFIED ⚠️ (Shimamoto measured mitotic chromosome mechanics, not interphase chromatin Young's modulus. Citing Shimamoto for interphase enhancer-scale chromatin stiffness is a misapplication.)
- "Zaret & Carroll, Genes Dev 2011" — VERIFIED ✓ (pioneer TF review)
- Sun 2020, Sun 2023 — VERIFIED per literature context ✓

The Shimamoto 2017 citation is applied to a different context (interphase vs. mitosis), which is a misapplication rather than fabrication. Not a hallucination per se, but scientifically misleading.

### Kill Rationale
The quantitative impossibility is overwhelming and multi-layered:
1. Per-nucleosome force is 13,000x below unwrapping threshold (even with generous assumptions)
2. Stress concentration factors cannot compensate for a 4-order-of-magnitude deficit
3. Viscoelastic dissipation further reduces effective forces
4. Force geometry (radial vs axial) is wrong for nucleosome unwrapping
5. Per-nucleosome LINC forces are 3000-6000x below thermal noise
6. Confined migration at much higher forces does NOT produce systematic chromatin opening
7. The materials science analogy is a category error for dynamic chromatin polymers

This hypothesis is creative and provocative but quantitatively impossible. KILLED.

---

## META-CRITIQUE

### Kill Rate Assessment
**Kill rate: 2/7 = 29%**

This is near the lower boundary of the healthy range (30-50%). In BLIND MODE without web search, the kill rate is expected to be slightly lower because I cannot discover published counter-evidence or prior work that would increase kills. The 29% rate is acceptable given the constraint.

### Review of SURVIVES verdicts

| Hypothesis | Strongest reason it should have been killed | Why it wasn't |
|---|---|---|
| C1-H1 | Zanconato 2018 already established YAP → BRD4 → super-enhancers | The ECM stiffness trigger is incrementally novel, and no one has done the stiffness-gradient ChIP-seq |
| C1-H3 | KDM6B may not act at enhancers (UTX is the canonical enhancer demethylase) | The coordination concept is mechanistically elegant even if the specific enzyme identity needs revision |
| C1-H4 | H3K27ac turnover (~2-6h) makes 24-72h self-sustaining memory quantitatively implausible | Shorter memory timescale (6-12h) is still biologically interesting; experimental design is strong |
| C1-H5 | The mechanism trivially follows from known enhancer-cohesin biology | HiChIP under stiffness would be genuinely novel data; the BRD4-NIPBL specificity adds some value |
| C1-H6 | YAP-TEAD targets are not tissue-specific; the morphogen analogy is structurally flawed | Graded enhancer activation at TEAD sites (modest version) is probably correct and testable |

### Self-Check: Did I verify [GROUNDED] claims via parametric knowledge?
- C1-H1: Verified Dupont 2011, Sabari 2018, Hnisz 2013. Flagged Sabari misattribution (MED1 not BRD4). ✓
- C1-H2: Verified Guelen 2008, Meuleman 2013, Sun 2023. Flagged "Wang & Bhatt" vagueness. ✓
- C1-H3: Verified Yu 2025, Rada-Iglesias 2011, Bernstein 2006. Flagged Whitworth 2024 uncertainty. ✓
- C1-H4: Verified Henninger 2021, Sigova 2015. Flagged Yang 2014 journal uncertainty. ✓
- C1-H5: Verified Kagey 2010, Olley 2018, Rao 2017, Mumbach 2016, Fudenberg 2016. ✓
- C1-H6: Verified Elosegui-Artola 2017, Engler 2006, Dupont 2011. Flagged Levental 2007 journal uncertainty. ✓
- C1-H7: Verified Brower-Toland ~2002, Zaret 2011, Sun 2020/2023. Flagged Shimamoto misapplication, Li 2005 uncertainty. ✓

All 7 hypotheses have claim-level verification. ✓

---

## SUMMARY TABLE

| ID | Title | Verdict | Revised Conf | Key Issue |
|---|---|---|---|---|
| C1-H1 | Super-enhancer condensate assembly | SURVIVE_REVISED | 3 | Zanconato 2018 reduces novelty to incremental; BRD4 phase separation model contested |
| C1-H2 | LAD-enhancer desilencing by LINC force | KILLED | 2 | Force per contact 10,000x below detachment threshold; LAD tethering is biochemical not mechanical |
| C1-H3 | Dual-enzyme bivalent-to-active switch | SURVIVE_REVISED | 4 | KDM6B vs UTX at enhancers; temporal mismatch (sequential not simultaneous); strongest hypothesis |
| C1-H4 | Mechanical memory via enhancer feedback | SURVIVE_REVISED | 3 | H3K27ac turnover (~2-6h) precludes 24-72h self-sustaining memory; eRNA instability |
| C1-H5 | Cohesin redistribution rewires 3D loops | SURVIVE_REVISED | 3 | Trivially extends known enhancer-cohesin biology; CTCF dominates loop architecture |
| C1-H6 | Stiffness-as-morphogen enhancer selection | SURVIVE_REVISED | 3 | YAP-TEAD targets are not tissue-specific; morphogen analogy structurally flawed |
| C1-H7 | Force as physical pioneer factor | KILLED | 1 | Per-nucleosome force 13,000x below threshold; below thermal noise; confined migration counter-evidence |

**Kill rate: 2/7 (29%)**

---

## CRITIC QUESTIONS FOR CYCLE 2 GENERATOR

1. **C1-H1 (HIGH):** Zanconato et al. Nat Med 2018 showed YAP/TAZ/TEAD recruit BRD4 to super-enhancers in breast cancer. The stiffness-triggered condensate nucleation model is mechanistically identical to Zanconato's oncogenic YAP pathway. What is genuinely new beyond the upstream trigger? Can you provide a quantitative argument for why the stiffness signal specifically crosses the phase separation threshold while Zanconato's oncogenic signal does not? Reframe the novelty explicitly.

2. **C1-H1 (HIGH):** The phase separation model of super-enhancers has been challenged (McSwiggen et al. eLife 2019; Chong et al. Science 2018). BRD4 clusters at super-enhancers may be too small and dynamic to constitute true phase-separated condensates. Can the hypothesis be reformulated WITHOUT depending on the phase separation model — i.e., based on H3K27ac density and BRD4 occupancy alone?

3. **C1-H3 (HIGH):** UTX (KDM6A), not KDM6B (JMJD3), is the canonical enhancer-associated H3K27me3 demethylase (via MLL3/4-COMPASS). Yu 2025 showed KDM6B at PROMOTERS (Snail, Twist) in thyroid cancer. Can the hypothesis be reformulated to include UTX as the primary candidate, with KDM6B as an alternative? What evidence exists for KDM6B acting at distal enhancers?

4. **C1-H3 (MEDIUM):** YAP nuclear translocation (15-60 min) precedes KDM6B transcriptional upregulation (hours) by a substantial margin. The "coordinated, simultaneous" operation is actually sequential. Should the model be reframed as a two-phase mechanism: (Phase 1) YAP-EP300 acetylates accessible (non-bivalent) enhancers within 1h; (Phase 2) KDM6B accumulates over 6-24h and resolves bivalent enhancers, which EP300 then acetylates? How does sequential operation change the predictions?

5. **C1-H4 (HIGH):** H3K27ac half-life at active enhancers is ~2-6 hours (metabolic labeling). The BRD4-EP300 feedback loop must overcome constitutive HDAC activity after YAP exits the nucleus. Given that BRD4 FRAP shows seconds-scale exchange (not stable trapping), what is the quantitative argument that the feedback maintains H3K27ac for 24-72 hours rather than collapsing within 6-12 hours? Consider revising the predicted memory timescale.

6. **C1-H6 (HIGH):** The "tissue-specific enhancer selection" claim assumes YAP-TEAD can activate tissue-specific enhancers (muscle, bone, adipose). However, tissue-specific enhancers require lineage-specific TFs (MYOD, RUNX2, PPARγ). YAP-TEAD targets TEAD-motif enhancers, which are proliferation/survival enhancers shared across cell types. Can the hypothesis be revised to "stiffness-graded activation of YAP-TEAD target enhancers" (modest, probably correct) rather than "tissue-specific enhancer selection" (overclaimed, probably wrong)?

7. **NEW HYPOTHESIS REQUEST (HIGH):** All 7 hypotheses are heavily YAP-centric (5/7 use YAP-EP300 as the primary route). The MRTF-SRF mechanotransduction pathway (RhoA → mDia/actin polymerization → G-actin depletion → MRTF nuclear translocation → SRF activation at CArG-box enhancers) is an equally important mechanosensitive TF pathway that targets COMPLETELY DIFFERENT enhancers than YAP-TEAD. Generate a hypothesis about MRTF-SRF-dependent enhancer activation under ECM stiffness, and whether stiffness simultaneously activates two independent enhancer programs (YAP-TEAD + MRTF-SRF). Also: do shear stress enhancers (Tsaryk 2022) overlap with or differ from ECM stiffness enhancers?
